MKA
GILD icon

M. Kulyk & Associates’s Gilead Sciences GILD Stock Holding History

M. Kulyk & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46M Buy
74,859
+1,160
+2% +$153K 1.54% 24
2026
Q1 		$10.3M Sell
73,699
-270
-0.4% -$37.8K 1.92% 16
2025
Q4 		$9.08M Buy
73,969
+1,655
+2% +$201K 1.73% 19
2025
Q3 		$8.03M Sell
72,314
-1,939
-3% -$220K 1.63% 20
2025
Q2 		$8.23M Buy
74,253
+1,384
+2% +$147K 1.79% 16
2025
Q1 		$8.17M Sell
72,869
-15,797
-18% -$1.63M 1.87% 17
2024
Q4 		$8.19M Sell
88,666
-11,801
-12% -$1.06M 1.77% 17
2024
Q3 		$8.42M Sell
100,467
-3,412
-3% -$260K 1.69% 17
2024
Q2 		$7.13M Buy
103,879
+14,651
+16% +$978K 1.66% 20
2024
Q1 		$6.54M Buy
89,228
+5,795
+7% +$446K 1.52% 23
2023
Q4 		$6.76M Sell
83,433
-919
-1% -$71.5K 1.57% 22
2023
Q3 		$6.32M Buy
84,352
+1,337
+2% +$103K 1.76% 14
2023
Q2 		$6.4M Sell
83,015
-5,855
-7% -$467K 1.79% 15
2023
Q1 		$7.37M Buy
88,870
+1,021
+1% +$84.6K 2.23% 12
2022
Q4 		$7.54M Sell
87,849
-193
-0.2% -$15.3K 2.52% 9
2022
Q3 		$5.43M Buy
88,042
+1,572
+2% +$99.1K 1.89% 13
2022
Q2 		$5.34M Buy
86,470
+3,275
+4% +$203K 1.66% 17
2022
Q1 		$4.95M Sell
83,195
-19,076
-19% -$1.22M 1.35% 29
2021
Q4 		$7.43M Buy
102,271
+5,329
+5% +$367K 1.92% 14
2021
Q3 		$6.77M Buy
96,942
+4,741
+5% +$333K 2.17% 10
2021
Q2 		$6.35M Buy
92,201
+9,122
+11% +$609K 2.29% 9
2021
Q1 		$5.37M Buy
83,079
+28,219
+51% +$1.82M 2% 11
2020
Q4 		$3.2M Buy
+54,860
New +$3.31M 1.77% 25

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

M. Kulyk & Associates's GILD Position: Q2 2026 in Review

M. Kulyk & Associates increased its Gilead Sciences (GILD) stake by 1.6% in Q2 2026, buying an estimated $153K and bringing the position to 74,859 shares worth $9.46M. The position accounts for 1.54% of the portfolio, ranked #24.

M. Kulyk & Associates first reported a position in GILD in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.3M in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • M. Kulyk & Associates held 74,859 shares of Gilead Sciences worth $9.46M as of Q2 2026.
  • M. Kulyk & Associates bought 1,160 Gilead Sciences shares in Q2 2026, an estimated $153K.
  • Gilead Sciences made up 1.54% of M. Kulyk & Associates's portfolio in Q2 2026, its #24 holding.
  • M. Kulyk & Associates first reported a position in Gilead Sciences in Q4 2020 and has held it in 23 quarters since.
  • M. Kulyk & Associates's Gilead Sciences position peaked at $10.3M in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on M. Kulyk & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.